Cosmo Pharmaceuticals Sa Stock Fundamentals
| COPN Stock | CHF 63.20 0.40 0.64% |
COSMO Pharmaceuticals SA fundamentals help investors to digest information that contributes to COSMO Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of COSMO Stock. The fundamental analysis module provides a way to measure COSMO Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to COSMO Pharmaceuticals stock.
COSMO |
COSMO Pharmaceuticals SA Company Operating Margin Analysis
COSMO Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current COSMO Pharmaceuticals Operating Margin | 0.25 % |
Most of COSMO Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, COSMO Pharmaceuticals SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, COSMO Pharmaceuticals SA has an Operating Margin of 0.2457%. This is 100.7% lower than that of the Healthcare sector and 98.78% lower than that of the Drug Manufacturers - Major industry. The operating margin for all Switzerland stocks is 104.46% lower than that of the firm.
COSMO Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining COSMO Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare COSMO Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across COSMO Pharmaceuticals competition to find correlations between indicators driving COSMO Pharmaceuticals's intrinsic value. More Info.COSMO Pharmaceuticals SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.22 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for COSMO Pharmaceuticals SA is roughly 4.65 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the COSMO Pharmaceuticals' earnings, one of the primary drivers of an investment's value.COSMO Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses COSMO Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of COSMO Pharmaceuticals could also be used in its relative valuation, which is a method of valuing COSMO Pharmaceuticals by comparing valuation metrics of similar companies.COSMO Pharmaceuticals is currently under evaluation in operating margin category among its peers.
COSMO Fundamentals
| Return On Equity | 0.0841 | |||
| Return On Asset | 0.0181 | |||
| Profit Margin | 0.45 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 960.99 M | |||
| Shares Outstanding | 16.38 M | |||
| Shares Owned By Insiders | 47.28 % | |||
| Shares Owned By Institutions | 11.80 % | |||
| Price To Earning | 95.06 X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 12.95 X | |||
| Revenue | 65.07 M | |||
| Gross Profit | 32.1 M | |||
| EBITDA | 40.36 M | |||
| Net Income | 21.67 M | |||
| Cash And Equivalents | 217.97 M | |||
| Cash Per Share | 14.53 X | |||
| Total Debt | 169.03 M | |||
| Debt To Equity | 35.50 % | |||
| Current Ratio | 24.38 X | |||
| Book Value Per Share | 28.23 X | |||
| Cash Flow From Operations | 12.61 M | |||
| Earnings Per Share | 2.13 X | |||
| Target Price | 86.03 | |||
| Number Of Employees | 292 | |||
| Beta | 1.07 | |||
| Market Capitalization | 1.12 B | |||
| Total Asset | 805.56 M | |||
| Z Score | 3.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 805.56 M | |||
| Last Dividend Paid | 0.95 |
About COSMO Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze COSMO Pharmaceuticals SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of COSMO Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of COSMO Pharmaceuticals SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. COSMO PHARM operates under Drug Manufacturers - Major classification in Switzerland and is traded on Switzerland Exchange. It employs 306 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for COSMO Stock Analysis
When running COSMO Pharmaceuticals' price analysis, check to measure COSMO Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSMO Pharmaceuticals is operating at the current time. Most of COSMO Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of COSMO Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSMO Pharmaceuticals' price. Additionally, you may evaluate how the addition of COSMO Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.